Therapiefortschritte bei aggressiven Lymphomen:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | German |
| Veröffentlicht: |
Bremen ; London ; Boston
UNI-MED Verlag AG
[2015]
|
| Ausgabe: | 2. Auflage |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 141 Seiten Illustrationen, Diagramme 25 cm |
| ISBN: | 9783837415049 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV043690998 | ||
| 003 | DE-604 | ||
| 005 | 20170309 | ||
| 007 | t | ||
| 008 | 160728s2015 a||| |||| 00||| ger d | ||
| 015 | |a 16,A18 |2 dnb | ||
| 016 | 7 | |a 1081647655 |2 DE-101 | |
| 020 | |a 9783837415049 |c Festeinband : EUR 39.80 |9 978-3-8374-1504-9 | ||
| 035 | |a (OCoLC)933211260 | ||
| 035 | |a (DE-599)DNB1081647655 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a ger | |
| 049 | |a DE-578 |a DE-355 | ||
| 082 | 0 | |a 616.9944206 |2 22/ger | |
| 084 | |a YC 2715 |0 (DE-625)153204:12921 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 084 | |a WH 525 |2 nlm | ||
| 245 | 1 | 0 | |a Therapiefortschritte bei aggressiven Lymphomen |c Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren] |
| 250 | |a 2. Auflage | ||
| 264 | 1 | |a Bremen ; London ; Boston |b UNI-MED Verlag AG |c [2015] | |
| 300 | |a 141 Seiten |b Illustrationen, Diagramme |c 25 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Lymphom |0 (DE-588)4036760-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Lymphom |0 (DE-588)4036760-5 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Pfreundschuh, Michael |d 1949-2018 |0 (DE-588)108615871 |4 edt |4 aut | |
| 700 | 1 | |a Bittenbring, Jörg Thomas |d 1977- |0 (DE-588)131985051 |4 aut | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://d-nb.info/1081647655/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029103666&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029103666 | ||
Datensatz im Suchindex
| _version_ | 1804176465319690240 |
|---|---|
| adam_text | INHALTSVERZEICHNIS
EINLEITUNG UND HISTORISCHE ASPEKTE 1 YY
1.YY.
LITERATUR....................................................................................................................................................
YY
3
EPIDEMIOLOGIE UND BIOLOGIE 15
2.1.
EPIDEMIOLOGIE.......................................................................................................................................
15
2.2.
AETIOLOGIE................................................................................................................................................16
2.2.1.
IMMUNSUPPRESSION...................................................................................................................................17
2.2.2
INFEKTIONEN...............................................................................................................................................17
2.2.3. CHEMISCHE SUBSTANZEN, NAHRUNGS- UND
UMWELTFAKTOREN.................................................................17
2.2.4. GENETISCHE
FAKTOREN..............................................................................................................................18
2.2.5. CHRONISCHE
IMMUNSTIMULATION...............................................................................................................18
2.3
LITERATUR....................................................................................................................................................18
MOLEKULARE BIOLOGIE UND GENETIK AGGRESSIVER LYMPHOME 21
3.1. MOLEKULARBIOLOGIE AGGRESSIVER LYMPHOME
......................................................................................
21
3.1 .YY
. GENOMYYSCHE ALTERATIONEN BEYY AGGRESSIVEN
LYMPHOMEN.....................................................................21
3.1.1. YY.
TRANSLOKATIONEN.........................................................................................................................................21
3.1.2. GENEXPRESSIONSANALYSEN BEI AGGRESSIVEN
LYMPHOMEN.......................................................................25
3.2.
LITERATUR.................................................................................................................................................
29
PATHOLOGIE 33
4.1.
DEFINITION................................................................................................................................................33
4.2.
UEBERSICHT................................................................................................................................................34
4.3. DIFFUSES GROSSZELLIGES B-ZELL-LYMPHOM
(DLBCL).............................................................................34
4.3.1. DLBCL, NICHT WEITER SPEZIFIZIERT
(NOS)...................................................................................................34
4.3.2 MOLEKULARE UND MMUNHISTOCHEMISCH DEFINIERTE SUBGRUPPEN
..........................................................
35
4.3.3 DEFINIERTE SUBTYPEN UND KLINISCHE ENTITAETEN DES
DLBCL......................................................................35
4.3.3.1.
BURKITT-LYMPHOM.....................................................................................................................................37
4.4.
GRAUZONEN-LYMPHOME.......................................................................................................................37
4.5 PERIPHERE YY/YYYY-ZELL-LYMPHOME
(PTCL).............................................................................................38
4.5.1. PRIMAER LEUKAEMISCHE
LYMPHOME............................................................................................................38
4.5.2. PRIMAER NODALE
YY/YYYY-ZELL-LYMPHOME....................................................................................................38
4.5.3 PRIMAER EXTRANODALE PERIPHERE
NK/T-ZELL-LYMPHOME...........................................................................40
4.6
LITERATUR....................................................................................................................................................40
KLINISCHES ERSCHEINUNGSBILD 41
5.1. PERIPHERE
LYMPHADENOPATHIE.............................................................................................................41
5.2. EXTRALYMPHATISCHER
BEFALL....................................................................................................................41
5.3.
MEDIASTINALERBEFALL...............................................................................................................................42
5.4. M
ILZ..........................................................................................................................................................42
5.5.
ALLGEMEINSYMPTOME.............................................................................................................................42
5.6 SONSTIGE KLINISCHE
SYMPTOME.............................................................................................................
43
5.7.
KLINISCHERVERLAUF..................................................................................................................................43
5.8.
LITERATUR...................................................................................................................................................43
DIFFERENZIALDIAGNOSE, D
YYAG
O 45
6.1.
DIFFERERENZIALDIAGNOSE..........................................................................................................................45
6.2.
DYYAGNOSESYYCHERUNG.............................................................................................................................45
6.2.1. AUSFUEHRUNG DER
BIOPSIE............................................................................................................................46
6.2.2. HYYST
0
YY
0
GYYSCHEYY
BEFUNDBERICHT...............................................................................................................
46
6.3. WEITERGEHENDE DIAGNOSTIK/
STAGING.................................................................................................47
6.3.1.
LABOR.......................................................................................................................................................47
6.3.2. BILDGEBENDE
VERFAHREN..........................................................................................................................47
63.3. INVASIVE
DIAGNOSTIK.................................................................................................................................47
6.3.4. SONSTIGE UNTERSUCHUNGEN VOR
THERAPIEBEGINN...................................................................................48
6.4. AUFKLAERUNG DES
PATIENTEN...................................................................................................................48
PROGNOSTISCHE FAKTOREN UND THERAPIEGRUPPEN 5YY
7.1.
DEFINITION................................................................................................................................................51
7.2. PROGNOSEFAKTOREN DES
IPI.....................................................................................................................51
7.3. PROGNOSEFAKTOREN UND THERAPEUTISCHE SUBGRUPPEN
.........................................................................
54
7.4. IM IPYY NICHT BERUECKSICHTIGTE
PROGNOSEFAKTOREN...............................................................................54
7.4.1. LYMPHOM-ASSOZIIERTE
PARAMETER..............................................................................................................54
7.4.1.1. HISTOLOGISCHER
SUBTYP..............................................................................................................................54
7.4.1 YY2.
IMMUNPHAENOTYP........................................................................................................................................55
7.4.1.3.
GENEXPRESSYYONSPROFILE................................................................................................................................55
7.4.1.4.
ZYTOGENETIK................................................................................................................................................57
7YY4.YY
.5. MYC-BRUCHE, BCL2-BYYUECHE, DOUBLEHITS UND TRIPLEHITS
............................................................................
57
7.4.1.6. EXPRESSION VON MYCYY UND
BCL2-PROTEINEN.................................................................................................58
7.4.2 PATIENTEN-ASSOZIIERTE
PARAMETER..............................................................................................................59
7.4.3 THERAPLE-ASSOZIIERTE
PARAMETER..............................................................................................................61
7.5. KLINISCHE WERTIGKEIT VON
PROGNOSEFAKTOREN....................................................................................62
7.6.
LITERATUR..................................................................................................................................................62
PRIMAERTHERAPIE DER AGGRESSIVEN B-ZEYY-LYMPHOME 72
8.1 CHIRURGIEYY
YY
YY
YY
YY
YY
YY
YY
.YY
YY
YY
YY
YY
.YY
8.2.
STRAHLENTHERAPIE...................................................................................................................................73
8.2.1. AHEINIGE
STRAHLENTHERAPJE......................................................................................................................73
8.2.2 KOMBINIERTE (IMMUNO-) CHEMOSTRAHLENTHERAPIE MIT VERKUERZTER
CHEMOTHERAPIE................. 73
8.2.3 KONSOLIDIERENDE STRAHLENTHERAPIE ALS ADDITIVE
MASSNAHME..................................................................74
8.3.
CHEMOTHERAPIE........................................................................................
75
8.3.1.
VORPHASE-THERAPIE..................................................................................................................................77
8.3.2
STANDARDCHEMOTHERAPIE..........................................................................................................................77
8.3.3.
ZYKLUSZAHL...............................................................................................................................................78
8.3.4.
VITAMIN-D-SUBSTITUTION..........................................................................................................................79
8.4. RISIKOADAPTIERTE
THERAPIESTRATEGIEN.................................................................................................80
8.4.1. AELTERE
PATIENTEN.......................................................................................................................................81
8.4.1.1. ALTERE PATIENTEN OHNE WEITEREN RISIKOFAKTOR UND OHNE YYYY
/YY
....................................................................
90
8.4.1 YY2. ALLE UEBRIGEN AELTERE PATIENTEN (61 -80 JAHRE, IPI=1 MIT BULK,
IPI=2-5)............................................................91
8.4.1.3. SEHR ALTE
PATIENTEN...................................................................................................................................91
8.4.1.4. GEBRECHLICHE ( FRAGILE )
PATIENTEN.................................................................................................................92
8.4.2. JUNGE
PATIENTEN......................................................................................................................................93
8.4.2. YY. JUNGE PATIENTEN MIT GUTER PROGNOSE,
FOVOUROBLE ....................................................................................94
8422. JUNGE PATIENTEN MIT GUTER PROGNOSE, UNFAVOURABLE
................................................................................
94
8.4.2.3. JUNGE PATIENTEN MIT UNGUENSTIGER PROGNOSE
(AALPI==2,3)...........................................................................96
8.4.3. EXTRANODALE
NHL............................................................................................................................
99
8.4.4. SPEZIELLE THERAPIEANSAETZE FUER HISTOLOGISCH DEFINIERTE SUBGRUPPEN
AGGRESSIVER LYMPHOME...... 99
8.4.5. THERAPIE DER SEHR AGGRESSIVEN
LYMPHOME...................................................................................100
8.5 PROPHYLAXE UND THERAPIE EINES
ZNS-BEFALLS...............................................................................101
8.6.
NEBENWIRKUNGEN........................................................................................................................101
QQ
LITERATUR.......................................................................................................................................102
THERAPIE PERIPHERER T-ZELL-LYMPHOME 110
9.1.
PRIMAERTHERAPIE...........................................................................................................................110
9.2.
REZIDIVTHERAPIE.........................................................................................................................113
9.3
LITERATUR.......................................................................................................................................
YY
15
REZIDIVTHERAPIE UND NEUE SUBSTANZEN BEI AGGRESSIVEN LYMPHOMEN 1YY
7
YY 0.1. ZWEITLINIENTHERAPIE: KONVENTIONELLE
REZIDIVPROTOKOLLE...........................................................YY
YY 7
10.2. HOCHDOSISTHERAPIE UND AUTOLOGE
STAMMZELLTRANSPLANTATION.................................................118
10.3. PROGNOSTISCHE FAKTOREN BEI PATIENTEN MIT REZIDIV EINES AGGRESSIVEN
NHL.................120
10.4.
ALLOGENESTAMMZEMTRANSPLANTATION...........................................................................................YY
21
10.5. NEUE
SUBSTANZEN......................................................................................................................YY
24
10.6.
LITERATUR.....................................................................................................................................125
KOMPLEMENTAERE UND ALTERNATIVE THERAPIEN 131
11.1.
DEFINITIONEN................................................................................................................................13YY
11 YY2.
BEWEGGRUENDE.............................................................................................................................YY
31
11.3YY
EPIDEMIOLOGIE.............................................................................................................................131
I YY YY4. WIRKSAMKEIT DER ALTERNATIVEN UND KOMPLEMENTAEREN
LYMPHOMTHERAPIEN YY 32
11.4.1 VITAMINE UND
MINERALIEN.............................................................................................................132
YY 1 YY4.2.
PHYTOTHERAPIE..............................................................................................................................132
11.4.3.
HOMOEOPATHIE..............................................................................................................................YY
32
11.4.4.
AKUPUNKTUR.................................................................................................................................133
11.4.5.
HYPNOSE......................................................................................................................................YY
33
II YY4.6.
MEDITATION.....................................................................................................................................133
11.4.7. SPIRITUELLE
HEILVERFAHREN...............................................................................................................YY
33
5.
NEBENWIRKUNGEN.........................................................................................................................133
YY
1.6. UMGANG MIT ALTERNATIVEN THERAPIEVERFAHREN
...........................................................................
133
.7.
LITERATUR........................................................................................................................................
134
ERNAEHRUNG UND LIFESTYLE 136
12.1 GENERELLE
EMPFEHLUNGEN..........................................................................................................YY
36
12.2 ERNAEHRUNG UND
LYMPHOME.........................................................................................................
136
YY 2.3 BESONDERE ASPEKTE DER ERNAEHRUNG BEI LYMPHOMPATIENTEN
..................................................
YY 36
12.4 BESONDERE
DIAETEN........................................................................................................................
YY
36
YY 2.5 EINFLUSS VON CHEMO- UND
STRAHLENTHERAPIE..............................................................................YY
37
12.6. KOERPERLICHES TRAINING UND
SPORT.................................................................................................137
12.7. PSYCHOLOGISCHE
UNTERSTUETZUNG..................................................................................................137
12.8.
LITERATUR.........................................................................................................................1
3
7
INDEX 140
|
| any_adam_object | 1 |
| author | Pfreundschuh, Michael 1949-2018 Bittenbring, Jörg Thomas 1977- |
| author2 | Pfreundschuh, Michael 1949-2018 |
| author2_role | edt |
| author2_variant | m p mp |
| author_GND | (DE-588)108615871 (DE-588)131985051 |
| author_facet | Pfreundschuh, Michael 1949-2018 Bittenbring, Jörg Thomas 1977- Pfreundschuh, Michael 1949-2018 |
| author_role | aut aut |
| author_sort | Pfreundschuh, Michael 1949-2018 |
| author_variant | m p mp j t b jt jtb |
| building | Verbundindex |
| bvnumber | BV043690998 |
| classification_rvk | YC 2715 |
| ctrlnum | (OCoLC)933211260 (DE-599)DNB1081647655 |
| dewey-full | 616.9944206 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9944206 |
| dewey-search | 616.9944206 |
| dewey-sort | 3616.9944206 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. Auflage |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01881nam a2200457 c 4500</leader><controlfield tag="001">BV043690998</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20170309 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">160728s2015 a||| |||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">16,A18</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1081647655</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837415049</subfield><subfield code="c">Festeinband : EUR 39.80</subfield><subfield code="9">978-3-8374-1504-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)933211260</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1081647655</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-578</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9944206</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2715</subfield><subfield code="0">(DE-625)153204:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WH 525</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapiefortschritte bei aggressiven Lymphomen</subfield><subfield code="c">Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">141 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">25 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Lymphom</subfield><subfield code="0">(DE-588)4036760-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Lymphom</subfield><subfield code="0">(DE-588)4036760-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfreundschuh, Michael</subfield><subfield code="d">1949-2018</subfield><subfield code="0">(DE-588)108615871</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bittenbring, Jörg Thomas</subfield><subfield code="d">1977-</subfield><subfield code="0">(DE-588)131985051</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://d-nb.info/1081647655/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029103666&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029103666</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV043690998 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:32:37Z |
| institution | BVB |
| isbn | 9783837415049 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029103666 |
| oclc_num | 933211260 |
| open_access_boolean | |
| owner | DE-578 DE-355 DE-BY-UBR |
| owner_facet | DE-578 DE-355 DE-BY-UBR |
| physical | 141 Seiten Illustrationen, Diagramme 25 cm |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | UNI-MED Verlag AG |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Therapiefortschritte bei aggressiven Lymphomen Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren] 2. Auflage Bremen ; London ; Boston UNI-MED Verlag AG [2015] 141 Seiten Illustrationen, Diagramme 25 cm txt rdacontent n rdamedia nc rdacarrier UNI-MED science Lymphom (DE-588)4036760-5 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Lymphom (DE-588)4036760-5 s Therapie (DE-588)4059798-2 s DE-604 Pfreundschuh, Michael 1949-2018 (DE-588)108615871 edt aut Bittenbring, Jörg Thomas 1977- (DE-588)131985051 aut B:DE-101 application/pdf http://d-nb.info/1081647655/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029103666&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Pfreundschuh, Michael 1949-2018 Bittenbring, Jörg Thomas 1977- Therapiefortschritte bei aggressiven Lymphomen Lymphom (DE-588)4036760-5 gnd Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4036760-5 (DE-588)4059798-2 (DE-588)4143413-4 |
| title | Therapiefortschritte bei aggressiven Lymphomen |
| title_auth | Therapiefortschritte bei aggressiven Lymphomen |
| title_exact_search | Therapiefortschritte bei aggressiven Lymphomen |
| title_full | Therapiefortschritte bei aggressiven Lymphomen Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren] |
| title_fullStr | Therapiefortschritte bei aggressiven Lymphomen Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren] |
| title_full_unstemmed | Therapiefortschritte bei aggressiven Lymphomen Prof. Dr. Michael Pfreundschuh ; unter Mitarbeit von Dr. Jörg-Thomas Bittenbring [und 15 weiteren] |
| title_short | Therapiefortschritte bei aggressiven Lymphomen |
| title_sort | therapiefortschritte bei aggressiven lymphomen |
| topic | Lymphom (DE-588)4036760-5 gnd Therapie (DE-588)4059798-2 gnd |
| topic_facet | Lymphom Therapie Aufsatzsammlung |
| url | http://d-nb.info/1081647655/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029103666&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT pfreundschuhmichael therapiefortschrittebeiaggressivenlymphomen AT bittenbringjorgthomas therapiefortschrittebeiaggressivenlymphomen |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis